Platelet News and Research

RSS

Actelion launches new 20 mcg/mL Ventavis formulation

Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance.

2 Sep 2009

PLATO study reveals that ticagrelor reduces the rate of cardiovascular events

The presentation of the PLATO (A Study of Platelet Inhibition and Patient Outcomes), showed that ticagrelor (Brilinta) reduced the rate of cardiovascular (CV) events (CV death, myocardial infarction or stroke) from 11.7% to 9.8% compared clopidogrel (Plavix®) XX% (p<0.001, RRR = 16%), without an increase in major bleeding.

2 Sep 2009

Cordis enrolls first patient in the CYPRESS clinical study

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.

31 Aug 2009

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Cardium Therapeutics today reported that a recent medical journal article highlights the challenges facing healthcare providers with respect to finding optimal treatments for patients with non-healing wounds.

28 Aug 2009

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Patients with a certain genetic variation who received the antiplatelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event in the following year than patients who did not have this variant, according to a study in the August 26 issue of JAMA.

25 Aug 2009

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Portola Pharmaceuticals, Inc. today announced two oral presentations at the European Society of Cardiology (ESC) Congress 2009 in Barcelona, Spain, that will feature its investigational antiplatelet drug elinogrel, a P2Y12 ADP receptor antagonist that is currently in Phase II clinical development with Novartis, Portola's development and commercialization partner.

25 Aug 2009

University of Southampton develops a microfluidic single-cell impedance cytometer for blood cell analysis

A hand-held device which could offer point-of-care blood cell analysis in doctors' surgeries is being developed by academics at the University of Southampton and is described in a paper in Lab on a Chip this month.

25 Aug 2009

FDA approves Extavia for multiple sclerosis

The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.

17 Aug 2009

Research on blood transfusions points to a potential risk of transfusing donated platelets

Doctors have noticed a pattern in performing bone marrow transplants as a cure for diseases involving bone marrow failure: more transfusions before a bone marrow transplant correlates with a higher likelihood of rejection, says James Zimring, MD, PhD, assistant professor of pathology and laboratory medicine at Emory University School of Medicine.

12 Aug 2009

Genzyme’s Mozobil approved in Europe

Genzyme Corporation announced today that the European Commission has granted marketing authorization for Mozobil ® (plerixafor injection), providing a significant new option for patients with the blood cancers lymphoma and multiple myeloma who require an autologous stem cell transplant.

6 Aug 2009

Links between major depression and coronary artery disease studied

Major depression and coronary artery disease are only modestly related throughout an individual’s lifetime, but studying how the two interact over time and in twin pairs paints a more complex picture of the associations between the conditions, according to a report in the August issue of Archives of General Psychiatry. For example, the association between coronary artery disease onset and major depression risk is much stronger over time than vice versa.

4 Aug 2009

Aspirin and an anti-clotting drug ‘combo’ reduces risk of dialysis access failure

For the first time, a combination of aspirin and the anti-platelet drug dipyridamole has been shown to significantly reduce blockages and extend the useful life of new artery-vein access grafts used for hemodialysis, according to a study by the Dialysis Access Consortium (DAC).

21 May 2009

Toddler’s mysterious meningitis trumps cancer threat

Brooklynn Spencer's mother Samantha knew something wasn't right. The 8 month old had the flu recently, but it had been four weeks. She should have been better. The Elmira mother of four pushed for blood tests in early October 2007. A few hours later, there was a knock at the door.

21 May 2009

Genetic variations may contribute to depression in heart disease patients

Individuals with heart disease are twice as likely to suffer from depression as the general population, an association the medical community has largely been unable to explain.

19 May 2009

Pazopanib shows promise for aggressive thyroid cancer

A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates.

17 May 2009

More patients needed in clinical trials to find treatment for patent foramen ovale (PFO)

The American Heart Association and the American College of Cardiology are calling on doctors to enroll more patients in clinical trials for catheter-based closure of patent foramen ovale (PFO), a condition caused when an opening between the two chambers of the heart fails to close at birth.

12 May 2009

Acetylsalicylic acid plus clopidogrel reduces heart attack risk in patients with acute ischaemia

In order to better prevent blood clots, clopidogrel can be prescribed to patients with acute ischaemia of the heart muscle, in addition to acetylsalicylic acid (ASA).

22 Apr 2009

Research may lead to new ways to fight clot formation

When plaques coating blood vessel walls rupture and expose collagen, platelets spring into action to form a blood clot at the damaged site.

16 Apr 2009

Anti-clotting medications may be associated with brain microbleeds in older adults

Individuals who take aspirin or other medications that prevent blood clotting by inhibiting the accumulation of platelets appear more likely to have tiny, asymptomatic areas of bleeding in the brain, according to a report posted online today that will appear in the June print issue of Archives of Neurology.

13 Apr 2009

Gene delivery appears safe for regenerating tooth-supporting gum tissue

Scientists at the University of Michigan have developed a method of gene delivery that appears safe for regenerating tooth-supporting gum tissue---a discovery that assuages one of the biggest safety concerns surrounding gene therapy research and tissue engineering.

8 Apr 2009

Platelet News and Research

Actelion launches new 20 mcg/mL Ventavis formulation

PLATO study reveals that ticagrelor reduces the rate of cardiovascular events

Cordis enrolls first patient in the CYPRESS clinical study

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

University of Southampton develops a microfluidic single-cell impedance cytometer for blood cell analysis

FDA approves Extavia for multiple sclerosis

Research on blood transfusions points to a potential risk of transfusing donated platelets

Genzyme’s Mozobil approved in Europe

Links between major depression and coronary artery disease studied

Aspirin and an anti-clotting drug ‘combo’ reduces risk of dialysis access failure

Toddler’s mysterious meningitis trumps cancer threat

Genetic variations may contribute to depression in heart disease patients

Pazopanib shows promise for aggressive thyroid cancer

More patients needed in clinical trials to find treatment for patent foramen ovale (PFO)

Acetylsalicylic acid plus clopidogrel reduces heart attack risk in patients with acute ischaemia

Research may lead to new ways to fight clot formation

Anti-clotting medications may be associated with brain microbleeds in older adults

Gene delivery appears safe for regenerating tooth-supporting gum tissue

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News